Genmab A (GMAB) Total Non-Current Liabilities (2019 - 2026)
Genmab A's (GMAB) quarterly Total Non-Current Liabilities came in at $5.5 billion in Q1 2026, up 932.96% YoY from $534.0 million in Q1 2025, and down 1.48% on a QoQ basis from $5.6 billion in Q4 2025.
Genmab A (GMAB) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Total Non-Current Liabilities data on file, last reported at $5.5 billion in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 932.96% year-over-year to $5.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 billion (up 932.96% YoY) and the FY2025 annual result came in at $5.6 billion, up 950.47% from the prior year.
- Total Non-Current Liabilities slipped to $5.5 billion in Q1 2026, from $5.6 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $5.6 billion in Q4 2025 to a low of $177.0 million in Q4 2023.
- A 4-year average of $1.9 billion and a median of $533.0 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 201.13% — and 2025, when it soared 950.47%.
- Tracing GMAB's Total Non-Current Liabilities over 4 years: stood at $177.0 million in 2023, then soared by 201.13% to $533.0 million in 2024, then soared by 950.47% to $5.6 billion in 2025, then dropped by 1.48% to $5.5 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $5.5 billion (Q1 2026), $5.6 billion (Q4 2025), and $529.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 5.42 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.42 Bn |
| Mar 31, 2026 | 5.52 Bn |
| Dec 31, 2025 | 5.60 Bn |
| Sep 30, 2025 | 529.00 Mn |
| Jun 30, 2025 | 533.00 Mn |
| Mar 31, 2025 | 534.00 Mn |
| Dec 31, 2024 | 533.00 Mn |
| Dec 31, 2023 | 177.00 Mn |
| Sep 30, 2020 | 787.00 |
| Dec 31, 2019 | 158.00 |
| Sep 30, 2019 | 160.91 Mn |